12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PT003: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 237 patients showed that twice-daily PT003, PT001 and PT005 administered via a metered dose inhaler met the primary endpoint of no significant change in mean heart rate over 24 hours vs. open-label 12...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >